Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$11.3M
4M shares
52-week range
$1.92 – $74.94
2% from low
Exchange
NASDAQ
CS
Borrow rate
50.24%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $240 | $4.3K | $0 |
| Gross profit | $0 | $0 | −$240 | −$4.3K | $0 |
| Gross margin | — | — | — | — | — |
| R&D | $137.2K | $1.6M | $954.6K | $342.2K | $1.5M |
| Operating income | −$334.3K | −$4.4M | −$2.8M | −$3.7M | −$6.2M |
| EBITDA | $10.5M | $10.8M | −$51.1M | $1.0M | −$6.9M |
| Net income | $8.2M | $8.0M | −$51.2M | $1.0M | −$6.9M |
| Net margin | — | — | — | — | — |
| EPS (diluted) | 0.25 | -0.64 | -7.85 | 1.78 | 0.00 |
Annual figures · source: Financial Modeling Prep
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
www.psyence.comNo one on the platform currently holds PBM.
No tracked institution reports a position in PBM as of their last filing.
| Execution date | Ratio |
|---|---|
| 2026-02-02 | 1-for-6.25reverse |
| 2025-05-05 | 1-for-7.97reverse |
| 2024-11-26 | 1-for-75reverse |
No one on the platform has traded PBM yet.
| $5M |
| — |
| INDPIndaptus Therapeutics, Inc. | $3.06 | -10.26% | $5M | — |
| LIPOLipella Pharmaceuticals Inc. | $0.06 | -35.56% | $268009 | — |
Source: Financial Modeling Prep · peers by sector/industry
@RkyMtnChi likewise I also hold $CMPS and $PBM. (I have a preference for psilocybin as the active in the context of mental health treatment - naturally occuring, stood the test of time in our evolutionary history - and benign).
View on StockTwits ↗$PBM we had the premarket spike 2 or so weeks back 80k volume to 3.80 before it dropped off before open, then not much volume 20-40k but the last few days seems like its coming to life 50k+ with momentum building, hopefully and update is imminent
View on StockTwits ↗$PBM shorted the 200k available then returned them, then took them all back out seems odd, thats a large chunk of the float though, squeeze it
View on StockTwits ↗$PBM sector on fire today slap that arsk, break out inbound
View on StockTwits ↗$PBM added more since it went below my average ...come onn mannn
View on StockTwits ↗$PBM 7k down to 700 quid ,was 2k up when I sold but bought more when price dropped now I've stopped putting more in until I recover this one gla
View on StockTwits ↗$PBM Add to a core...down more here than almost everything else on a glance. Letting it ride though for awhile. GLTY.
View on StockTwits ↗$PBM just need some news and actual volume, the tiniest bit of buying and up it goes every time
View on StockTwits ↗@RuddyRolls commercial availability for $PBM is 3-5 years away. $CMPS for example is end of this year early next year.
View on StockTwits ↗$PBM sector on fire today, got to expect a little $DFTX love to come our way shortly. We are the most leveraged psychedelics bet available for those who've made bank and want to reinvest some of the profits.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.